Routine Evaluation of People Living With Cancer

Overview

People with incurable cancer often have complex individual needs, however there are several common themes encountered when considering this group. As cancer progresses there are series of interactions between the tumour and the patient, producing both local and systemic effects. This altered state of illness can have multiple ill effects including weight loss, fatigue, increased symptom burden and reduction in physical function which all contribute to a reduced quality of life. These areas are often studied in isolation, giving an incomplete picture. A detailed, holistic characterisation of this group of people does not exist. A robust characterisation of people with incurable cancer will allow identification and prioritisation of future research and has the potential to inform new therapeutics and provide justification for treatments. This study aims to collect information about symptoms and quality of life, weight loss and body composition, physical activity and the body's immune response to cancer. Participants with incurable cancer will be recruited to the study from oncology and palliative medicine services in the UK. Participants will answer questionnaires about quality of life and symptoms, have bloods taken for inflammatory marker and cytokine analysis and have their body composition measured by a variety of methods.

Full Title of Study: “Routine Evaluation of People Living With Cancer – Body Composition, Physical Function, Systemic Inflammatory Response, Quality of Life and Symptoms”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: August 8, 2029

Clinical Trial Outcome Measures

Primary Measures

  • Association between inflammatory cytokines and clinical parameters in incurable cancer
    • Time Frame: 2 years
    • Correlation of serum levels of inflammatory cytokines with clinical parameters including skeletal muscle mass, symptom based scores and physical activity as measured by actigraphy.

Participating in This Clinical Trial

Inclusion Criteria

  • Patients with incurable cancer (metastatic cancer (Clinical, histological, cytological or radiological evidence) or receiving anti-cancer therapy with palliative intent). – Aged 18-years and over – Written informed consent Exclusion Criteria:

  • Any concomitant medical or psychiatric problems which, in the opinion of the investigator, would increase the risk of complication for the participant and/or investigator. – Participants will not be able to take part in bio-impedance analysis if they have a pacemaker or implantable cardiac defibrillator.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Edinburgh
  • Collaborator
    • NHS Lothian
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Barry JA Laird, MBCHB MD, Principal Investigator, St Columba’s Hospice/ University of Edinburgh
  • Overall Contact(s)
    • Barry JA Laird, MBCHB MD, 01316518611, barry.laird@ed.ac.uk

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.